

# Maximising Opportunities Overcoming Challenges

## Respiratory




Respiratory drug development and commercialisation encompass improvements in existing classes of systemic and inhaled treatments as well as novel agents for common and rare respiratory conditions. Finding effective and safe new classes of drugs to treat asthma and COPD remains difficult. tranScrip teams have expertise in all major respiratory indications from asthma, COPD and allergy to orphan indications such as cystic fibrosis or idiopathic pulmonary fibrosis. We are helping our clients address clinical and regulatory challenges, differentiate their products and realise drug development and lifecycle goals.

# Diverse Programmes Effective Execution

A snapshot of our recent projects



# Insightful Collaborations Seamless Integration



## What we will do

When there is a problem or gap, we will become your long-term partner and create a way together to resolve the issue.

## Why are we so confident?

Working as long-term partners, our respiratory teams integrate seamlessly with our clients. We provide effective support by delivering strategic insights and innovative approaches to all aspects of respiratory drug development, from translational science through to registration and medical affairs, worldwide.

## tranScrip has a proven track record of achievements that include:

- Designing and delivering large, complex, cross-functional respiratory programmes
- Serving as the drug development organisation for small biotech companies
- Interpreting 'difficult' outcomes in clinical trials and steering discussions with the regulatory authorities
- Fielding multi-functional submission teams to author and deliver MAAs and NDAs
- Providing management and oversight for all drug safety needs
- Designing and delivering tailored training programmes for product launches